1032 related articles for article (PubMed ID: 26329342)
1. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE;
J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342
[TBL] [Abstract][Full Text] [Related]
2. Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes.
Barra L; Bykerk V; Pope JE; Haraoui BP; Hitchon CA; Thorne JC; Keystone EC; Boire G;
J Rheumatol; 2013 Aug; 40(8):1259-67. PubMed ID: 23378461
[TBL] [Abstract][Full Text] [Related]
3. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis.
Barra L; Pope JE; Orav JE; Boire G; Haraoui B; Hitchon C; Keystone EC; Thorne JC; Tin D; Bykerk VP;
J Rheumatol; 2014 Dec; 41(12):2361-9. PubMed ID: 25274884
[TBL] [Abstract][Full Text] [Related]
5. Should we redefine treatment targets in rheumatoid arthritis? Low disease activity is sufficiently strict for patients who are anticitrullinated protein antibody-negative.
de Punder YM; Hendrikx J; den Broeder AA; Valls Pascual E; van Riel PL; Fransen J
J Rheumatol; 2013 Aug; 40(8):1268-74. PubMed ID: 23729803
[TBL] [Abstract][Full Text] [Related]
6. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.
Katchamart W; Koolvisoot A; Aromdee E; Chiowchanwesawakit P; Muengchan C
Rheumatol Int; 2015 Oct; 35(10):1693-9. PubMed ID: 25903353
[TBL] [Abstract][Full Text] [Related]
7. Antibodies to porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives.
Hitchon CA; Chandad F; Ferucci ED; Willemze A; Ioan-Facsinay A; van der Woude D; Markland J; Robinson D; Elias B; Newkirk M; Toes RM; Huizinga TW; El-Gabalawy HS
J Rheumatol; 2010 Jun; 37(6):1105-12. PubMed ID: 20436074
[TBL] [Abstract][Full Text] [Related]
8. Should anti-citrullinated protein antibody and rheumatoid factor status be reassessed during the first year of followup in recent-onset arthritis? A longitudinal study.
Mjaavatten MD; van der Heijde DM; Uhlig T; Haugen AJ; Nygaard H; Bjørneboe O; Kvien TK
J Rheumatol; 2011 Nov; 38(11):2336-41. PubMed ID: 21965645
[TBL] [Abstract][Full Text] [Related]
9. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z
J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216
[TBL] [Abstract][Full Text] [Related]
10. Antibodies against citrullinated peptides are associated with clinical and radiological outcomes in patients with early rheumatoid arthritis: a prospective longitudinal inception cohort study.
Boman A; Brink M; Lundquist A; Hansson M; Mathsson-Alm L; Rönnelid J; Berglin E; Holmdahl R; Skriner K; Serre G; Klareskog L; Rantapää-Dahlqvist S
RMD Open; 2019; 5(2):e000946. PubMed ID: 31565241
[TBL] [Abstract][Full Text] [Related]
11. Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort.
Mouterde G; Rincheval N; Lukas C; Daien C; Saraux A; Dieudé P; Morel J; Combe B
Arthritis Res Ther; 2019 Jun; 21(1):140. PubMed ID: 31171038
[TBL] [Abstract][Full Text] [Related]
12. Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration.
Chatzidionysiou K; Lukina G; Gabay C; Hetland ML; Hauge EM; Pavelka K; Nordström D; Canhão H; Tomsic M; Rotar Z; Lie E; Kvien TK; van Vollenhoven RF; Saevarsdottir S
Scand J Rheumatol; 2019 Jan; 48(1):17-23. PubMed ID: 30260261
[TBL] [Abstract][Full Text] [Related]
13. Association of anti-cyclic citrullinated peptide antibodies with clinical and radiological disease severity in rheumatoid arthritis.
Gupta A; Kaushik R; Kaushik RM; Saini M; Kakkar R
Curr Rheumatol Rev; 2014; 10(2):136-43. PubMed ID: 25599684
[TBL] [Abstract][Full Text] [Related]
14. The Canadian Early Arthritis Cohort (CATCH): patients with new-onset synovitis meeting the 2010 ACR/EULAR classification criteria but not the 1987 ACR classification criteria present with less severe disease activity.
Bykerk VP; Jamal S; Boire G; Hitchon CA; Haraoui B; Pope JE; Thorne JC; Sun Y; Keystone EC
J Rheumatol; 2012 Nov; 39(11):2071-80. PubMed ID: 22896026
[TBL] [Abstract][Full Text] [Related]
15. Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria.
Nordberg LB; Lillegraven S; Lie E; Aga AB; Olsen IC; Hammer HB; Uhlig T; Jonsson MK; van der Heijde D; Kvien TK; Haavardsholm EA;
Ann Rheum Dis; 2017 Feb; 76(2):341-345. PubMed ID: 27094444
[TBL] [Abstract][Full Text] [Related]
16. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.
Mustila A; Korpela M; Haapala AM; Kautiainen H; Laasonen L; Möttönen T; Leirisalo-Repo M; Ilonen J; Järvenpää S; Luukkainen R; Hannonen P
Clin Exp Rheumatol; 2011; 29(3):500-5. PubMed ID: 21640044
[TBL] [Abstract][Full Text] [Related]
17. Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis.
Abdel-Nasser AM; Mahmoud MH; El Mansoury TM; Osman AM
Scand J Rheumatol; 2008; 37(5):329-36. PubMed ID: 18666028
[TBL] [Abstract][Full Text] [Related]
18. Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort.
Arnold MB; Bykerk VP; Boire G; Haraoui BP; Hitchon C; Thorne C; Keystone EC; Pope JE;
Rheumatology (Oxford); 2014 Jun; 53(6):1075-86. PubMed ID: 24501240
[TBL] [Abstract][Full Text] [Related]
19. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
[TBL] [Abstract][Full Text] [Related]
20. Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment.
Di Muzio G; Perricone C; Ballanti E; Kroegler B; Greco E; Novelli L; Conigliaro P; Cipriani P; Giacomelli R; Perricone R
Int J Immunopathol Pharmacol; 2011; 24(2):357-66. PubMed ID: 21658310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
